News & Updates

Urological prosthetic surgery: Which men are at risk of postoperative thromboembolism?
Urological prosthetic surgery: Which men are at risk of postoperative thromboembolism?
27 Sep 2022
Radical prostatectomy tied to higher survival than radiotherapy in prostate cancer
Radical prostatectomy tied to higher survival than radiotherapy in prostate cancer
27 Sep 2022
Poor sleep quality may increase odds of erectile dysfunction
Poor sleep quality may increase odds of erectile dysfunction
26 Sep 2022

Sleep parameters are robust predictors of erectile dysfunction (ED), suggesting that poor sleep quality contributes to a greater likelihood of ED, reveals a study.

Poor sleep quality may increase odds of erectile dysfunction
26 Sep 2022
Mirabegron benefits men with OAB, erectile dysfunction
Mirabegron benefits men with OAB, erectile dysfunction
26 Sep 2022
PDE5-I use poses no excess cardiovascular, mortality risk in diabetic men with ED
PDE5-I use poses no excess cardiovascular, mortality risk in diabetic men with ED
20 Sep 2022

The presence of erectile dysfunction (ED) does not appear to confer an increased risk of cardiovascular disease (CVD) and mortality in men with diabetes mellitus (DM), with comparable risk of adverse cardiovascular events among users and nonusers of phosphodiesterase-5 inhibitors (PDE5-Is), which are used to manage ED, according to a study.

PDE5-I use poses no excess cardiovascular, mortality risk in diabetic men with ED
20 Sep 2022
Maximal androgen blockade the prime prostate cancer treatment option in older patients
Maximal androgen blockade the prime prostate cancer treatment option in older patients
16 Sep 2022

Among prostate cancer patients aged ≥75 years, maximal androgen blockage (MAB) appears to be the most common treatment option, reports a new South Korea study. Meanwhile, the combination of leuprolide and bicalutamide is the most common MAB regimen.

Maximal androgen blockade the prime prostate cancer treatment option in older patients
16 Sep 2022